Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 2/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | METAP2 | P50579 | 2/20 | 0.37 |
| ▸ | NOS1 | P29475 | 4/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | DHPS | P49366 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MET | P08581 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20182527 | 0.80 | AXL (0.50) | AXLIDO1METAP2NOS1TRPA1 | |
| SCHEMBL19308820 | 0.74 | KDM4E (0.43) | IDO1KDM4EPDPK1CYP3A4GAA | |
| SCHEMBL10285272 | 0.72 | AXL (0.62) | AXLIDO1METAP2NOS1TRPV1 | |
| SCHEMBL13948936 | 0.71 | KDM4E (0.46) | IDO1KDM4EPDPK1CYP3A4GAA | |
| SCHEMBL19308854 | 0.71 | KDM4E (0.46) | IDO1KDM4EPDPK1CYP3A4GAA | |
| SCHEMBL2627058 | 0.70 | AXL (0.68) | AXLIDO1METAP2NOS1TRPV1 | |
| SCHEMBL9229130 | 0.70 | KDM4E (0.39) | IDO1KDM4EPDPK1CYP3A4GAA | |
| SCHEMBL347644 | 0.67 | KDM4E (0.52) | IDO1KDM4EPDPK1CYP3A4GAA | |
| SCHEMBL12683720 | 0.64 | AXL (1.00) | AXLIDO1METAP2NOS1TRPV1 | |
| SCHEMBL30446607 | 0.64 | KDM4E (0.53) | IDO1KDM4EPDPK1CYP3A4GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10807948-B2 | Aromatic compounds and uses thereof | PELOTON THERAPEUTICS, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20180162807-A1 | AROMATIC COMPOUNDS AND USES THEREOF | PELOTON THERAPEUTICS, INC. | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10807948-B2 | Aromatic compounds and uses thereof | VHL, HIF1AN, HIF1A | AXL 1416/4885IDO1 257/4885METAP2 2657/4885 |
| US-20180162807-A1 | AROMATIC COMPOUNDS AND USES THEREOF | HIF1A, HIF1AN, VHL | AXL 1381/4885IDO1 1609/4885METAP2 3037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.